期刊
PHARMACOGENOMICS
卷 18, 期 14, 页码 1341-1357出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0010
关键词
bile duct cancer; cholangiocarcinoma; diagnosis; liquid biopsy; miRNA; prediction; prognosis
资金
- Bennink Foundation
- Associazione Italiana per la Ricerca sul Cancro
- Tuscany Region 'Bando Fas Salute'
- No Surrender Cancer Trust
- Action Against Cancer
- CCA Foundation
Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)-and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据